Scientists test drug binding in healthy lungs to guide future treatments
NCT ID NCT07362290
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study in 16 healthy volunteers aims to understand how the experimental drug XBD173 binds to a protein called TSPO in the lungs. Using PET scans, researchers will measure how much drug is needed to occupy TSPO, and whether food affects drug levels. The results will help design future studies for lung diseases like pulmonary arterial hypertension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XBD173
- What this could lead to
- If successful, this study could help design future trials for lung conditions like pulmonary arterial hypertension (PAH) by showing how to properly dose XBD173.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. It only measures drug binding, not whether the drug treats any disease. Results may not apply to sick people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NIHR Imperial CRF
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can paying attention to your body rewire your brain waves in 30 minutes?
- New lung imaging technique uses inhaled gas to see inside your lungs
- Quinoa cookie trial: a tasty way to fight obesity?
- New RNA drug ORN252 tested in humans for first time
- New drug QLS7305 tested in healthy volunteers – first step for future therapies
- New antibody drug aims to regrow hair – first human trial underway